Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01495845 · ClinicalTrials.gov registry record · Phase 1
Implementation of a Personalized Medicine (Pharmacogenomics) Service in a Community Pharmacy
A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT01495845 is a Phase 1 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 48 participants.
The verdict
NCT01495845, a Phase 1 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the feasibility of pharmacogenomics testing in a community pharmacy using clopidogrel as an example. The investigators hypothesize that this testing is feasible in this setting.
Interventions
- OTHER Pharmacogenomics testing for clopidogrel responsiveness
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2011-12 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01495845
The ClinicalTrials.gov registry entry for NCT01495845 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pharmacogenomics testing for clopidogrel responsiveness is the first listed.
NCT01495845 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01495845 about?
NCT01495845 is a clinical study titled "Implementation of a Personalized Medicine (Pharmacogenomics) Service in a Community Pharmacy". The purpose of this study is to determine the feasibility of pharmacogenomics testing in a community pharmacy using clopidogrel as an example. The investigators hypothesize that this testing is feasible in this setting.
What is the current status of trial NCT01495845?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2011-12. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01495845?
The interventions under investigation include: Pharmacogenomics testing for clopidogrel responsiveness (OTHER).
Who is sponsoring clinical trial NCT01495845?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.